Home / Recalls / Amgen, Inc. / D-0855-2022

D-0855-2022 Class II Terminated

Recalled by Amgen, Inc. — Thousand Oaks, CA

Recall Details

Product Type
Drugs
Report Date
May 18, 2022
Initiation Date
May 2, 2022
Termination Date
December 2, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
15,823

Product Description

MVASI (bevacizumab-awwb), Injection, For Intravenous Infusion After Dilution, 100 mg/4 ml, Single dose vial, Rx only, Manufactured by Amgen Inc. Thousand Oaks, CA 91320-1799, NDC 55513-0206-01

Reason for Recall

Defective container: loose crimp defect, potential loss of container integrity.

Distribution Pattern

Nationwide in the USA, Egypt and Lithuania.

Code Information

Lots: 1142258, 1143196, Exp. 09/24

Other recalls by Amgen, Inc.

  • D-0286-2025 Class II — Neupogen (filgrastim) For Injection, 480 mcg/1.6 mL (300 mcg/1 mL), 1.6 mL singl (February 27, 2025)
  • D-0285-2025 Class II — Neupogen (filgrastim) For Injection, 300mcg/1 mL, 1 mL Single Dose Vials, Rx Onl (February 27, 2025)
  • D-1173-2017 Class II — Procrit (epoetin alfa), 10,000 units/mL, packaged in a) box of 6 single use 1 mL (September 13, 2017)
  • D-1086-2017 Class II — Procrit Epoetin Alfa 40,000 units/mL single use vial For Intravenouse or Subcuta (August 4, 2017)
  • D-0226-2017 Class II — AMGEN Kyprolis (carfilzomib) for injection, 30 mg per vial, Discard unused port (December 15, 2016)
  • D-66318-001 Class II — Prolia (denosumab) Injection, 60 mg/mL, 1 x 60 mg Single Use Prefilled Syringe p (September 17, 2013)